Company Profile

Portola Pharmaceuticals Inc
Profile last edited on: 11/13/2023      CAGE: 5XNN2      UEI: FH2MKRASLYM3

Business Identifier: Therapeutics for acute and chronic cardiovascular, autoimmune & inflammatory diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

270 East Grand Avenue Suite 22
South San Francisco, CA 94080
   (650) 246-7000
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Portola Pharmaceuticals is a spinout of the majority of the COR Therapeutics assets acquired from Millennium Pharmaceuticals and is led by the former COR management team. Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options. The Company’s two lead programs address unmet medical needs in the area of thrombosis, or blood clots. The Company’s lead compound Betrixaban is an oral once-daily inhibitor of Factor Xa in Phase III development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism (VTE), in acute medically ill patients. The Company’s third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic, or blood, cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk), and janus kinases (JAK), enzymes that regulate signaling pathways.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $197,575
Project Title: Syk Blockade In Bullous Skin Diseases
2006 2 NIH $522,755
Project Title: Development of a Novel, Reversible P2Y12 Antagonist

Key People / Management

  William Lis -- Chief Executive Officer

  Pamela B Conley

  John Curnutte -- Executive Vice President, Research and Development

  Mark Gossett -- Senior Vice President, Commercial

  Charles Homcy -- former President

  Todd Lorenz -- Senior Vice President, Clinical Development and Scientific Licensing

  Jeet Mahal -- Vice President, Business Development

  David Phillips -- Senior Vice President

  Robert (Bob) Scarborough -- Senior Vice President

  Uma Sinha